150 likes | 288 Views
BHIVA 14th Annual Conference. April 2008, Belfast. Belfast Waterfront Hall. BHIVA 14th Annual Conference. 500 delegates 200 Poster presentations 30 oral abstracts 10 Satellite symposiums 5 Plenary sessions 3 big workshops
E N D
BHIVA 14th Annual Conference April 2008, Belfast Belfast Waterfront Hall
BHIVA 14th Annual Conference • 500 delegates • 200 Poster presentations • 30 oral abstracts • 10 Satellite symposiums • 5 Plenary sessions • 3 big workshops • Presentation of awards for 3 best abstracts of the conference by the Mayor of Belfast.
Relevant abstracts • Immunotherapy while delaying HAART • 350 CD4 threshold for starting therapy • Protease Inhibitors monotherapy • Diagnosing the undiagnosed • Ageing of the PLH population • HIV treatment adherence for adolescents • Community HIV treatment adherence support • The importance of home delivery for ARVs
Diagnosing the undiagnosed • Targeted prevention • Communities • Primary Care HIV testing • Background • CDC – routine testing of 13-64 olds to reduce late presentations • Methods • Past diagnosed prevalence for MSM and HS MSM - 0.25% prevalence and black women 2%
Diagnosing the undiagnosed • Conclusion • Localised approach of targeting offers HIV testing based on simple risk assessments. • It allows local patient acceptability, setting appropriateness and partner notification.
Protease Inhibitors mono-therapyThe KIMODO Study • Kaletra (Lopinavir + Ritonavir) monotherapy • Kaletra + Sustiva/Neviralpine • No significant difference between the two • Benefits • Less toxicity • Better adherence • Better resistance profile
Ageing of the PLH population • Cardiovascular disease • Diabetes • Dementia • Physical weakness • Care for elderly • Mobility • Sensory impairment • Living will/Funeral arrangements…
New Drugs • Celsentri (Maraviroc) – CCR5 antagonist • Isentress (Raltegravir) – Integrase inhibitor • Atripula od (Tenofovir+ Emtrica +Sustiva)